Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

To date, no compounds or interventions exist that treat or prevent sarcomeric cardiomyopathies. Established therapies currently improve the outcome, but novel therapies may be able to more fundamentally affect the disease process and course. Investigations of the pathomechanisms are generating molecular insights that can be useful for the design of novel specific drugs suitable for clinical use. As perturbations in the heart are stage-specific, proper timing of drug treatment is essential to prevent initiation and progression of cardiac disease in mutation carrier individuals. In this review, we emphasize potential novel therapies which may prevent, delay, or even reverse hypertrophic cardiomyopathy caused by sarcomeric gene mutations. These include corrections of genetic defects, altered sarcomere function, perturbations in intracellular ion homeostasis, and impaired myocardial energetics.

Original publication




Journal article


Cardiovasc Res

Publication Date





457 - 470


Dilated cardiomyopathy, Energetics and microvasculature, Gene therapy, Hypertrophic cardiomyopathy, Ion channels, Animals, Cardiomyopathies, Cardiovascular Agents, Energy Metabolism, Genetic Markers, Genetic Predisposition to Disease, Genetic Therapy, Humans, Molecular Targeted Therapy, Mutation, Phenotype, Sarcomeres, Signal Transduction